口服抗生素与静脉注射抗生素治疗骨折相关感染:POvIV随机临床试验
Oral vs Intravenous Antibiotics for Fracture-Related Infections: The POvIV Randomized Clinical Trial.
作者信息
Obremskey William T, O'Toole Robert V, Morshed Saam, Tornetta Paul, Murray Clinton K, Jones Clifford B, Scharfstein Daniel O, Taylor Tara J, Carlini Anthony R, DeSanto Jennifer M, Castillo Renan C, Bosse Michael J, Karunakar Madhav A, Seymour Rachel B, Sims Stephen H, Weinrib David A, Churchill Christine, Carroll Eben A, Pilson Holly T, Goodman James Brett, Holden Martha B, Miller Anna N, Sietsema Debra L, Stahel Philip F, Mir Hassan, Schmidt Andrew H, Westberg Jerald R, Mullis Brian, Shively Karl D, Hymes Robert A, Konda Sanjit R, Vallier Heather A, Breslin Mary Alice, Smith Christopher S, Crickard Colin V, Reid J Spence, Baker Mitch, Eglseder W Andrew, LeBrun Christopher, Manson Theodore, Mascarenhas Daniel C, Nascone Jason, Pollak Andrew N, Schloss Michael G, Sciadini Marcus F, Degani Yasmin, Miclau Theodore, Weiss David B, Yarboro Seth R, McVey Eric D, Firoozabadi Reza, Agel Julie, Burgos Eduardo J, Gajari Vamshi, Rodriguez-Buitrago Andres, Tummuru Rajesh R, Trochez Karen M
机构信息
Vanderbilt University Medical Center, Nashville, Tennessee.
R Adams Cowley Shock Trauma Center at the University of Maryland School of Medicine, Baltimore.
出版信息
JAMA Surg. 2025 Mar 1;160(3):276-284. doi: 10.1001/jamasurg.2024.6439.
IMPORTANCE
Fracture-related infection (FRI) is a serious complication following fracture fixation surgery. Current treatment of FRIs entails debridement and 6 weeks of intravenous (IV) antibiotics. Lab data and retrospective clinical studies support use of oral antibiotics, which are less expensive and may have fewer complications than IV antibiotics.
OBJECTIVE
To evaluate the effectiveness of treatment of FRI with oral vs IV antibiotics.
DESIGN, SETTING, AND PARTICIPANTS: The POvIV multicenter, prospective randomized clinical trial was conducted across 24 trauma centers in the US among patients aged 18 to 84 years who had fracture repair or arthrodesis with fixation with implants and developed an FRI without radiographic evidence of osteomyelitis. Patients were enrolled between March 2013 and September 2018 and followed up for 12 months after hospitalization for treatment of their FRI.
INTERVENTION
Oral vs IV antibiotics following FRI.
MAIN OUTCOMES AND MEASURES
The primary outcome was number of surgical interventions, and the primary hypothesis was noninferiority of oral vs IV antibiotics with respect to the number of study injury-related surgical interventions by 1 year. Unadjusted modified intent-to-treat (mITT) and adjusted per-protocol (PP) analyses were prespecified. A post hoc adjusted mITT analysis was conducted to resolve discrepancies between the results of the prespecified mITT and PP analyses. Recurrence of a deep surgical site infection was a key secondary outcome.
RESULTS
Among 233 total patients, mean (SD) age was 46.0 (13.9) years, and 53 patients were female (22.7%). The mean number of surgical interventions within 1 year was 1.3 and 1.1 for the oral and IV groups, respectively. The upper bound of the 95% confidence interval of the mean difference with unadjusted mITT analysis was 0.59, which was lower than the prespecified noninferiority margin of 0.67, indicating noninferiority of oral to IV antibiotics. Adjusted PP analysis did not support noninferiority of the number of reoperations. A post hoc adjusted mITT analysis also showed noninferiority. The treatment effects estimates for the key secondary outcome of reinfection showed a similar pattern as those for the primary outcome.
CONCLUSIONS AND RELEVANCE
In this prospective randomized clinical trial, oral antibiotic treatment was noninferior to IV treatment with respect to the primary outcome of number of surgical interventions based on mITT analysis. However, there is some uncertainty in these findings based on preplanned and post hoc secondary analyses. A similar pattern of treatment effect estimates was observed for the secondary outcome of recurrence of infection.
TRIAL REGISTRATION
ClinicalTrials.gov Identifier: NCT01714596.
重要性
骨折相关感染(FRI)是骨折内固定手术后的一种严重并发症。目前FRI的治疗需要清创术和6周的静脉注射(IV)抗生素治疗。实验室数据和回顾性临床研究支持使用口服抗生素,其成本较低,且可能比静脉注射抗生素的并发症更少。
目的
评估口服抗生素与静脉注射抗生素治疗FRI的有效性。
设计、设置和参与者:POvIV多中心前瞻性随机临床试验在美国24个创伤中心进行,纳入年龄在18至84岁之间、接受骨折修复或关节融合内固定术且发生FRI但无骨髓炎影像学证据的患者。患者于2013年3月至2018年9月入组,并在因FRI住院治疗后随访12个月。
干预措施
FRI后口服抗生素与静脉注射抗生素治疗。
主要结局和测量指标
主要结局是手术干预次数,主要假设是口服抗生素与静脉注射抗生素在1年内与研究损伤相关的手术干预次数方面非劣效。预先指定了未调整的意向性治疗(mITT)分析和调整后的符合方案(PP)分析。进行了事后调整的mITT分析以解决预先指定的mITT和PP分析结果之间的差异。深部手术部位感染的复发是一个关键的次要结局。
结果
在总共233例患者中,平均(标准差)年龄为46.0(13.9)岁,53例为女性(22.7%)。口服组和静脉注射组1年内的平均手术干预次数分别为1.3次和1.1次。未调整的mITT分析中,平均差异的95%置信区间上限为0.59,低于预先指定的非劣效界值0.67,表明口服抗生素相对于静脉注射抗生素非劣效。调整后的PP分析不支持再次手术次数的非劣效性。事后调整的mITT分析也显示非劣效。再感染这一关键次要结局的治疗效果估计与主要结局相似。
结论和相关性
在这项前瞻性随机临床试验中,基于mITT分析,在手术干预次数这一主要结局方面,口服抗生素治疗不劣于静脉注射治疗。然而,基于预先计划和事后的次要分析,这些结果存在一些不确定性。对于感染复发的次要结局,观察到了类似的治疗效果估计模式。
试验注册
ClinicalTrials.gov标识符:NCT01714596。